Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Bulgaria | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Malaysia | Mexico | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Unknown Location
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Anus Diseases|Diphtheria|Healthy Volunteers|Hepatitis|Influenza, Human|Poliomyelitis|Tetanus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2022-003923-17 | P3 |
Active, not recruiting |
Poliomyelitis |
2025-06-09 |
|
2021-006686-37 | P3 |
Active, not recruiting |
Tetanus|Hepatitis|Poliomyelitis|Anus Diseases|Diphtheria|Influenza, Human |
2023-08-08 |
|
CTR20160566 | P3 |
Active, not recruiting |
Healthy Volunteers |
None |